Article Text

Download PDFPDF
EV235/#1292  Value of KELIM as a prognostic biomarker in advanced ovarian cancer in a Mexican population
  1. Jairo Rubio-Cordero1,2,
  2. Guillermo Moreno-Flores2,
  3. Rebeca Ramírez2,
  4. Diego López-Enríquez2,
  5. Heidi Herrera-Estrella2,
  6. Mariana Villegas-Valenzuela2,
  7. Erick Raveles2,
  8. Pamela Martínez-Vega2 and
  9. David Cantu De Leon2
  1. 1Hospital General de México, Ciudad de Mexico, Mexico
  2. 2Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico

Abstract

Introduction Ovarian cancer (OC) is the deadliest gynecological neoplasm. Surgery is essential but advanced disease requires to initiate with neoadjuvant chemotherapy. Up to 80% of cases will have a response. Different biomarkers have been studied but access is limited. CA 125 elimination rate constant (KELIM), is validated as a biomarker. There is no information in Mexican population.

Methods Retrospective cohort of 151 patients with serous and endometrioid OC FIGO III-IV treated in a reference center in Mexico. KELIM score was calculated using the validated formula at https://www.biomarker-kinetics.org/CA-125-neo. Categorical variables were analyzed with chi-square and multivariable analysis with logistic regression. DFS and OS were analyzed using Kaplan-Meier curves compared with long-rank and multivariate analysis using Cox´s proportional hazard analysis.

Results Mean age was 51 years. Cut-off point of KELIM for complete (R0) surgery was 0.961 (OR 3.33; p=0.05) values equal or above were considered favorable and low as unfavorable. Favorable KELIM was associated with R0 surgery (p=0.041), chemotherapy response score 2 and 3 (p= 0.024), CA 125 values < 35 U/ml post-chemo (p= 0.001). Favorable KELIM was an independent prognostic factor for R0 (OR 2.4, IC 95% 1.08-5.5, p=0.032). Median DFS: 9 vs 28 months (p= 0.226) and median OS: 47 vs 72 months (HR 0.57; IC 95% 0.33-0.98, p= 0.04) for unfavorable and favorable KELIM, respectively.

Conclusion/Implications KELIM is an effective biomarker for complete cytorreduction in OC in Mexican population. Prospective validation trials are required.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.